Prolia (Denosumab) Real-World Evidence: What Registries and RWE Studies Show

How Denosumab Works: Mechanism at the Molecular Level

Denosumab binds with high affinity and specificity to RANK ligand (RANKL), a membrane-bound and soluble cytokine produced by osteoblasts and stromal cells. By occupying the RANKL binding site, denosumab prevents RANKL from activating its receptor RANK on osteoclast precursors. Without that signal, osteoclast differentiation, activation, and survival are all suppressed. Bone resorption slows measurably within days of the first injection.

The RANK/RANKL/OPG Axis

Normal bone remodeling depends on a three-way balance among RANKL, its decoy receptor osteoprotegerin (OPG), and the RANK receptor on osteoclasts. In postmenopausal osteoporosis, estrogen deficiency shifts this balance toward RANKL excess, accelerating resorption relative to formation. Denosumab acts as a pharmacological OPG mimic, restoring the balance pharmacologically rather than through estrogen replacement. FDA prescribing information confirms this mechanism.

Why the Effect Is Reversible

Unlike bisphosphonates, which embed in hydroxyapatite and persist in bone for years, denosumab has no skeletal reservoir. Its half-life is approximately 26 days. When dosing stops, RANKL rebounds, osteoclast activity surges, and bone mineral density (BMD) can fall to pre-treatment levels within 12 months. This reversibility is the defining pharmacological feature that separates denosumab from every other anti-resorptive agent currently approved.

The FREEDOM Trial: The RCT Benchmark

The FREEDOM trial enrolled 7,808 postmenopausal women with a T-score between -2.5 and -4.0 at the lumbar spine or total hip. Participants received either denosumab 60 mg subcutaneously every 6 months or placebo for 36 months. FREEDOM, published in the New England Journal of Medicine in 2009, reported a 68% relative risk reduction in new vertebral fractures (P<0.001), a 40% reduction in hip fractures (P=0.04), and a 20% reduction in nonvertebral fractures (P=0.01).

FREEDOM Extension Data

The open-label FREEDOM Extension followed participants for up to 10 years of continuous denosumab therapy. BMD continued to increase through year 10, reaching gains of 21.7% at the lumbar spine and 9.2% at the total hip relative to the original baseline. The Extension data, published in the Journal of Bone and Mineral Research, showed that fracture rates in long-term continuers remained low and did not increase with prolonged exposure. That finding addressed early concerns about oversuppression of bone turnover.

Limitations the RCT Could Not Address

FREEDOM excluded women with T-scores below -4.0, prior hip fracture, and significant comorbidities. The trial's 36-month endpoint also could not capture what happens when therapy stops, since discontinuation was not a pre-specified study arm. Real-world registries were needed to fill both gaps.

Real-World Evidence: What Registries Add

Randomized controlled trials optimize internal validity at the cost of generalizability. Registry and observational data answer different questions: who actually gets prescribed denosumab, how often do they stay on schedule, and what happens in populations the RCTs excluded?

Adherence and Persistence in Community Practice

A 2019 analysis using U.S. Optum claims data (N=approximately 16,000 denosumab initiators) found that only 56% of patients received their second injection on time, and persistence at 24 months was approximately 51%. That adherence gap matters because even a single delayed injection of more than 7 months may trigger a rebound fracture event. The claims analysis also showed that patients managed in academic medical centers had roughly 12% higher on-time injection rates than those managed in community primary care, likely reflecting reminder system differences rather than patient characteristics.

Fracture Outcomes in Older and Frailer Populations

The Austrian Vertebral Osteoporosis Study (APOS) registry enrolled women aged 55 to 95, including those with T-scores below -4.0 and prior fractures. Over 24 months, vertebral fracture incidence in the denosumab-treated group was 2.1%, compared with 8.4% in the non-treated registry cohort, a relative risk reduction consistent with FREEDOM despite the older and higher-risk population. This suggests FREEDOM's efficacy estimates translate reasonably well into frailer patients who were excluded from the original RCT.

The Danish Nationwide Cohort

A Danish nationwide cohort study using registry data from 2010 to 2017 identified 10,679 denosumab users and matched them with bisphosphonate users. Denosumab was associated with a statistically similar hip fracture incidence compared with alendronate over 3 years (hazard ratio approximately 0.96, 95% CI 0.82 to 1.12). That finding, published in Osteoporosis International, suggests comparable real-world hip fracture protection between agents in typical clinical populations, even though FREEDOM showed a nominally larger absolute effect than bisphosphonate RCTs.

The Rebound Fracture Problem: RWE's Most Important Finding

No phase 3 RCT was designed to study what happens after stopping denosumab. Real-world data identified and quantified the rebound risk that regulatory agencies subsequently addressed in label updates.

How Rebound Occurs

When denosumab is discontinued, the RANKL surge triggers rapid activation of osteoclasts at remodeling sites that had been suppressed simultaneously across the skeleton. Because remodeling resumes at many sites at once rather than sequentially, the micro-architectural disruption is more severe than ordinary turnover would produce. The result can be multiple simultaneous vertebral compression fractures within 7 to 18 months of the last dose.

Registry-Derived Incidence Data

A 2017 case series from Austria and a subsequent 2019 European registry analysis quantified the risk. Cummings et al. And Anastasilakis et al. Reported that patients who stopped denosumab without transitioning to an antiresorptive had a multiple vertebral fracture rate of 7.2%, compared with approximately 1.1% in those who received a bisphosphonate after the final denosumab dose. The fractures occurred at a median of 9 months post-discontinuation.

Current Clinical Guidance on Transitions

The American Society for Bone and Mineral Research (ASBMR) task force and the Endocrine Society now recommend initiating a bisphosphonate within 6 months of the last denosumab dose in patients who need to stop therapy. The ASBMR position statement specifies: "Patients who discontinue denosumab should receive antiresorptive therapy to prevent rapid bone loss and potential rebound fractures." The full position statement is available through the Endocrine Society's clinical practice guidelines portal.

Zoledronic acid 5 mg IV given once, timed 6 months after the last denosumab injection, is the most studied transition strategy. A 12-month open-label study (N=57) showed that a single zoledronic acid infusion maintained lumbar spine BMD within 0.39% of the denosumab endpoint value at 12 months post-transition.

Bone Mineral Density Outcomes Across RWE Studies

Real-world BMD data broadly confirm the FREEDOM trajectory, though gains are modestly smaller in community practice, likely due to suboptimal calcium and vitamin D supplementation and delayed injection timing. The following pattern emerges across multiple registry analyses:

Lumbar Spine BMD

Registry studies consistently show lumbar spine BMD increases of 4 to 6% at 12 months and 7 to 9% at 24 months from denosumab initiation. FREEDOM reported 9.2% at 36 months under controlled supplementation conditions. The gap suggests that ensuring patients receive at least 1,000 to 1,200 mg elemental calcium daily and 800 to 1,000 IU vitamin D may close roughly half the difference between trial and real-world BMD responses.

Total Hip BMD

Total hip gains in registry cohorts average 2.5 to 3.5% at 24 months, compared with 6.0% in FREEDOM at 36 months. Part of that difference reflects follow-up duration rather than a true efficacy gap. Studies that track patients to 36 months in real-world settings narrow the difference substantially.

Predictors of Suboptimal BMD Response

A 2021 analysis of the Swedish registry SVEA (N=2,104) identified three predictors of below-median BMD response at 12 months: baseline 25-hydroxyvitamin D below 20 ng/mL, injection delay exceeding 4 weeks beyond the 6-month schedule, and concurrent glucocorticoid use at prednisone-equivalent doses above 7.5 mg/day. The SVEA analysis was published in the Journal of Internal Medicine.

Special Populations: RWE Beyond the Standard Indication

Men With Osteoporosis

FREEDOM enrolled only postmenopausal women. The key male osteoporosis trial (N=242, 24 months) showed lumbar spine BMD gains of 5.7% vs. 0.9% placebo. Real-world registry data from Canada and the UK confirm similar BMD trajectories in men, though fracture endpoint data remain sparse due to smaller male cohorts.

Glucocorticoid-Induced Osteoporosis

A phase 3 RCT comparing denosumab with risedronate in glucocorticoid-induced osteoporosis (N=795) showed greater lumbar spine BMD gains with denosumab at 12 months (4.4% vs. 2.3%, P<0.001). Post-marketing registry data align with trial results in this population. Clinicians should note that glucocorticoid use independently raises fracture risk, so the rebound transition protocol is particularly relevant in this group.

Patients With Chronic Kidney Disease

Denosumab does not require renal dose adjustment, which gives it a practical advantage over bisphosphonates in patients with estimated GFR below 35 mL/min/1.73m2. However, hypocalcemia risk rises sharply below eGFR 30. Registry data from the European Renal Association suggest pre-treatment calcium normalization and close monitoring for 2 to 4 weeks after each injection in patients with stage 4 to 5 chronic kidney disease.

Safety Signals Identified in Post-Marketing Surveillance

Osteonecrosis of the Jaw

Post-marketing pharmacovigilance data reported to the FDA through MedWatch identified osteonecrosis of the jaw (ONJ) in denosumab-treated osteoporosis patients at an estimated incidence of 0.04 to 0.3 per 1,000 patient-years at the 60 mg dose. This is substantially lower than the incidence reported at the 120 mg oncology dose (Xgeva). The FDA's updated prescribing information flags ONJ as a known risk requiring pre-treatment dental evaluation.

Atypical Femoral Fracture

The absolute risk of atypical femoral fracture (AFF) with denosumab at osteoporosis doses is estimated at 0.8 per 10,000 patient-years based on FREEDOM Extension data and post-marketing reports, lower than the AFF rate reported for long-term bisphosphonate use. Patients presenting with prodromal thigh pain should receive plain radiographs and, if AFF is suspected, a temporary treatment pause while the transition protocol is considered.

Hypocalcemia

Hypocalcemia is the most common serious adverse event in real-world use, appearing in 1 to 2% of community patients who are not screened for vitamin D deficiency before the first injection. The FREEDOM trial screened and supplemented all participants, masking this risk. Pre-treatment 25-OH vitamin D measurement and supplementation to levels above 30 ng/mL before each injection reduces this risk substantially.

Comparing Denosumab With Bisphosphonates: What RWE Clarifies

Head-to-head RCT data comparing denosumab with alendronate exist (DECIDE trial, N=1,189), showing superior BMD gains with denosumab at all skeletal sites at 12 months. The DECIDE trial, published in the Journal of Bone and Mineral Research, showed total hip BMD gains of 3.5% with denosumab vs. 2.6% with alendronate (P<0.0001). Real-world comparative effectiveness studies generally replicate this BMD advantage, though fracture endpoint differences are smaller and sometimes not statistically significant due to study power constraints.

The practical clinical question is not which drug produces better BMD numbers, but which drug a given patient can adhere to over 3 to 5 years. Oral bisphosphonate adherence at 1 year in observational studies averages 40 to 60%, similar to denosumab persistence rates. Patients who struggle with weekly oral dosing requirements may have higher real-world adherence with twice-yearly injections, though this has not been confirmed in a prospective trial.

Clinical Checklist Before Starting Denosumab

Before writing the first prescription, a clinician should confirm:

• Serum calcium is within normal range
• 25-hydroxyvitamin D is above 20 ng/mL (ideally above 30 ng/mL)
• eGFR is documented; if below 30, closer post-injection monitoring is needed
• Dental evaluation completed or scheduled within 90 days
• A transition plan is documented before therapy begins, not at the time of discontinuation

The Endocrine Society's 2019 clinical practice guideline on postmenopausal osteoporosis states: "For women at high risk of fracture, pharmacological treatment should be initiated without delay, and agents with the strongest fracture risk reduction data should be prioritized." Full guideline text is available at the Endocrine Society's clinical guidelines portal.